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Abstract Diffusely infiltrating gliomas (WHO grade
II–IV) are the most common primary brain tumours in adults.
These tumours are not amenable to cure by surgery alone,
so suitable biomarkers for adjuvant modalities are required
to guide therapeutic decision-making. Epigenetic silencing
of the O6-methylguanine-DNA methyltransferase (MGMT)
gene by promoter methylation has been associated with
longer survival of patients with high-grade gliomas who
receive alkylating chemotherapy; and molecular testing for
the methylation status of the MGMT promoter sequence is
regarded as among the most relevant of such markers. We
have developed a primer extension-based assay adapted to
formalin-fixed paraffin-embedded tissues that enables
quantitative assessment of the methylation status of the
MGMT promoter. The assay is very sensitive, highly
reproducible, and provides valid test results in nearly 100%
of cases. Our results indicate that oligodendrogliomas,
empirically known to have a relatively favourable prog-
nosis, are also the most homogeneous entities in terms of
MGMT promoter methylation. Conversely, astrocytomas,
which are more prone to spontaneous progression to higher
grade malignancy, are significantly more heterogeneous. In
addition, we show that the degree of promoter methylation
correlates with the prevalence of loss of heterozygosity on
chromosome arm 1p in the oligodendroglioma group, but
not the astrocytoma group. Our results may have poten-
tially important implications for clinical molecular
diagnosis.
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Introduction
Diffusely infiltrating gliomas (WHO grade II–IV) account
for some 60% of primary brain tumours in adults. Based on
their microscopic morphology, the overwhelming majority
of these tumours may be assigned to either the astrocytoma
or the oligodendroglioma group, and a significant minority
(oligoastrocytomas) are felt to involve both tumour cell
types [1].
Astrocytomas of either grade (i.e., diffuse astrocytoma;
anaplastic astrocytoma; glioblastoma) are notorious for
pursuing a spontaneously progressive course, and tend to
respond poorly to adjuvant therapeutic modalities. Oligo-
dendroglial and oligoastrocytic tumours (i.e., oligoden-
droglioma; oligoastrocytoma; and anaplastic variants
thereof), on the other hand, have been known to behave in a
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comparatively less aggressive manner and to be remark-
ably responsive to alkylating drugs (e.g., temozolomide,
TMZ) [2]. They are characterized by a loss of heterozy-
gosity (LOH) of the chromosome arms 1p and 19q [3–6]
which, in most cases, is caused by an unbalanced
t(1;19)(q10;p19) translocation [4, 7, 8]. These deletions are
not only associated with longer survival of patients treated
with either chemotherapy or radiotherapy or combined
radiochemotherapy [4, 7, 8], but also constitute a treat-
ment-independent prognostic factor [4, 9, 10].
The cytotoxic effect of TMZ is mediated by DNA
alkylation of guanine residues. The DNA repair gene
O6-methylguanine-DNA methyltransferase (MGMT) is
responsible for removing alkyl groups from the O6 position
of guanine residues. Gliomas are heterogeneous with
regard to MGMT expression: in a subgroup of tumours this
gene is silenced by promoter methylation (reviewed by
Hegi et al. [11]). Consequently, it has been hypothesized
that methylation of the MGMT promoter may be a pre-
dictor of response to alkylating chemotherapy. Indeed,
Esteller et al. [12] and Hegi et al. [13, 14] showed that
patients whose tumours harbour a methylated MGMT
promoter sequence have significantly longer progression-
free and overall survival when treated with a combination
of radiation therapy and TMZ compared with patients with
an unmethylated MGMT promoter. Moreover, MGMT
promoter methylation has been shown to be a treatment-
independent favourable prognostic marker that could,
therefore, prospectively identify long-term survivors [14,
15]. These results were confirmed by the findings of the
European Organisation for Research and Treatment of
Cancer which demonstrated that MGMT promoter meth-
ylation was the strongest predictor of response to TMZ in
high-grade gliomas [16]. In contrast, the role of MGMT in
predicting response to TMZ in low-grade gliomas is less
clearly understood.
Although MGMT promoter methylation could be rou-
tinely used as a prognostic marker in glioblastomas, there
is so far no consensus on the method to be applied. In
most studies, the MGMT promoter methylation status was
assessed by means of methylation-specific polymerase
chain reaction (MSP) followed by a nested PCR and
agarose gel electrophoresis [12–14]. This method clearly
correlates with clinical response, but suffers from the
drawbacks that it is not quantitative and the failure rate
for formalin-fixed paraffin-embedded (FFPE) tissues is
relatively high. Semi-quantitative and quantitative meth-
ods including, quantitative MSP (qMSP) by real-time
PCR, methylation-specific multiplex ligation-dependent
probe amplification (MS-MLPA), and pyrosequencing
(reviewed by Laird [17]) have also been established, and
might even have higher predictive value than qualitative
MSP [18]. However, qualitative MSP is the only assay to
date that has been clinically validated in prospective
clinical trials [19].
Here we describe a simple, primer extension-based
assay which enables the methylation status of the MGMT
promoter to be assessed quantitatively. This method is very
sensitive, reproducible, and is adapted to FFPE tissues and
thus suitable for clinical use. We compared this method
with a modified MSP method for which the same primers
specific for methylated and unmethylated DNA were used
as for the gel-based method described by Esteller et al. [12]
and Hegi et al. [13, 14], and demonstrate that both methods
are in good agreement. To our knowledge, no study has
been reported on the heterogeneity of the intratumoural
methylation pattern of the MGMT promoter among glioma
entities. We provide evidence that glioblastomas, as a
group, have a significantly more heterogeneous pattern of
promoter methylation of the MGMT gene than oligoden-
drogliomas; this may potentially have implications for the
patient’s response to alkylating agents.
Materials and methods
Patient samples and cell lines
A total of 31 patients with oligodendrogliomas (WHO
grade II–III; mean age: 54 years; 17 male/14 female), 40
patients with oligoastrocytomas (WHO grade II–III; mean
age: 47 years; 24 male/16 female), 55 patients with astro-
cytomas (WHO grade II–III; mean age: 44 years; 30 male/
25 female), and 164 patients with glioblastoma (WHO
grade IV; mean age: 59 years; 104 male/60 female) were
analysed. Tissue diagnosis and specimen selection were
performed in a specialized surgical neuropathology setting
by two neuropathologists (MA and IV). Tumour classifi-
cation and grading was performed according to the criteria
defined by the current WHO Classification of Tumours of
the Central Nervous System [1]. All experiments using
human specimens were conduct in compliance with the
ethical guidelines of the Institute of Pathology at the Uni-
versity of Bern and were reviewed by the institutional
review board.
The human glioblastoma cell line U87 was kindly pro-
vided by M.E. Hegi, University of Lausanne.
DNA extraction and DNA modification
The age range of the FFPE tissue blocks used for DNA
extraction was between 1989 and 2008; 16% of the paraffin
blocks were older than four years. Tissue blocks were
carefully inspected by a neuropathologist. Tumour areas of
the infiltration zone, large necrotic regions, or regions
containing large numbers of inflammatory cells or blood
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vessels were excluded. Representative areas of tumour
containing at least 70% neoplastic cells were excised from
FFPE tissues and DNA was extracted using the EZ1 tissue
kit and the BioRobot EZ1 workstation (Qiagen, Hom-
brechtikon, Switzerland) according to the manufacturer’s
procedure with the modification that tissues were heat-
treated in lysis buffer for 10 min at 95C before proteinase
K digestion. For LOH analysis, reference DNA was
extracted from the patient’s EDTA peripheral blood using
the EZ1 tissue kit. The same kit was also used for
extraction of DNA from cell lines.
Bisulfite treatment was performed using the EZ DNA
modification kit according to the manufacturer’s procedure
(Zymo, Orange, CA, USA). The modified DNA was eluted
with 10 ll M-elution buffer and diluted with 10 ll water.
A control containing a mixture of equal amounts of
methylated (U87) and unmethylated (PBMC) DNA and a
no-DNA control were included in each experiment.
Quantitative MSP
In a first step, bisulfite-treated DNA was amplified by PCR
using the primer pair MU_forward (50-GGATATGTT
GGGATAGTT-30) and MU_rv (50-ACGCCTACAAAAC
CACTC-30) and 2 ll bisulfite-treated DNA. Both primer
binding sites contain no CpG dinucleotides, however, they
encompass CpG dinucleotides that are relevant for pre-
dicting chemoresistance. DNA from FFPE tissues is highly
fragmented. Therefore, primers were designed giving rise
to a short amplicon of only 169 bp which enables efficient
amplification of fragmented DNA.
In a second step, the PCR product was diluted 1:10 with
water and 2 ll was subjected to a multiplex primer
extension in a reaction containing 0.5 lM primer M_for-
ward_HEX (50-GCACTCTTCCGAAAACGAAACG-30),
0.5 lM primer U_forward_FAM (50-AACTCCACACTCT
TCCAAAAACAAAACA-30), 800 lM dNTPs, 1 U Taq,
and 19 Taq buffer (Applied Biosystems) in a total volume
of 30 ll. The forward primers were tagged with hexa-
chlorofluorescein (HEX) or 6-carboxyfluorescein (FAM),
respectively (Microsynth, Balgach, Switzerland). The
sequences of the primers are the same as those reported
previously [12–14, 20]. Primer extension was performed
for five cycles in a GeneAmp 9700 thermal cycler (Applied
Biosystems) using the conditions: 94C for 30 s, 62C for
30 s, and 72C for 30 s. The product was diluted 1:5 with
water and analysed by capillary electrophoresis using a
genetic analyser (ABI Prism 3100-Avant; Applied Bio-
systems, Rotkreuz, Switzerland) and GeneMapper software
4.0.
The percentage of methylated DNA was determined by
measuring the peak areas for methylated and unmethylated
DNA. The relative amount of methylated DNA was
normalized to the ratio of signal intensities obtained for a
control containing equal amounts of methylated and un-
methylated DNA performed in the same experiment. DNA
from peripheral blood monocytes was included as a nega-
tive control, which consistently gave rise to completely
unmethlylated DNA.
Qualitative MSP
Qualitative MSP was performed using primer pairs specific
for methylated (M_forward_HEX and M_rv (50-GTTTCG
ACGTTCGTAGGTTTTCGC-30)) or unmethyled (U_for-
ward_FAM and U_rv (50-GTTTGTGTTTTGATGTTTG
TAGGTTTTTGT-30)) DNA of the MGMT promoter and
2 ll bisulfite-treated DNA, which amplify fragments of
122 and 129-bp, respectively. In contrast with the pub-
lished MSP method [12–14], the first PCR step of the
nested PCR procedure was omitted. Alternatively, ampli-
fication was performed using the primer pair MU_forward
and MU_rv and the diluted product was re-amplified using
either the primer pair M-forward_HEX and M_rv or the
primer pair U_forward_FAM and U_rv. Analysis of PCR
products was performed by capillary electrophoresis.
LOH analysis
LOH analysis was performed exactly as described else-
where [10] using fluorescent primers tagged with HEX or
FAM for microsatellite markers on chromosome 1p36
(D1S468, D1S1612, D1S228 and D1S214) and chromo-
some 19q13 (D19S219, D19S412 and D19-HRC). PCR
products were analysed by capillary electrophoresis.
Diagnostic criteria for LOH required the calculated ratio of
the peak areas to be less than 0.5.
Cloning and sequencing
Bisulfite-treated DNA was amplified by PCR using the
primer pair MU_forward and MU_rv and cloned into
pGEM-T easy vector (Promega, Madison, WI, USA)
according the manufacturer’s procedure. The methylation
status of the MGMT promoter was determined by
sequencing of ten individual clones.
Statistics
Statistical analysis was performed by use of GraphPAD
prism software (San Diego, CA, USA). Statistical differ-
ences were calculated using an unpaired two-tailed
Student’s t-test. A probability of P \ 0.05 was considered
statistically significant. Statistical significance of correla-
tion was calculated by use of the N - 1 v2 test (2 9 2 table
Pearson’s analysis).
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Results
Establishment of a primer extension-based quantitative
MGMT promoter methylation assay
The successive reaction steps for the quantitative MGMT
promoter methylation assay are shown schematically in
Fig. 1a. In a first step, bisulfite-treated genomic DNA was
amplified using primers that are equally able to bind
methylated and unmethylated DNA. Both primer sites
encompass diagnostically relevant CpG dinucleotides
[12–14, 20]. To assess the methylation status, a multiplex
primer extension was performed using fluorescent-labelled
primers, which bind to CpG dinucleotides specific for the
methylated or unmethylated form of the DNA, followed by
capillary electrophoresis. If the assay were truly quantita-
tive, we would expect that the relative signal intensity of
fluorescent products reflects the proportion of methylated
DNA.
The quantitative assay was compared with a modified
version of the commonly used qualitative, gel-based assay.
In this case, bisulfite-treated DNA was amplified using
fluorescent-labelled primers specific for the methylated or
unmethylated form of the DNA, and analysed by capillary
electrophoresis (Fig. 1b).
Assay validation
Different control experiments were performed to validate
the quantitative methylation assay. To investigate the
specificity of the assay, untreated genomic DNA was
analysed; this, however, did not yield any product (data not
shown). Likewise, the primer specific for the unmethylated
form was unable to bind to bisulfite-treated, methylated
DNA (extracted from U87 cells), and the primer specific
for the methylated form was unable to bind to bisulfite-
treated, unmethylated DNA (extracted from peripheral
blood monocytes, data not shown).
To investigate whether the assay was quantitative, geno-
mic DNA from U87 and PBMC cells was mixed at different
concentrations and analysed for methylation status. In
Fig. 2, the relative intensity of the fluorescent signal for
methylated and unmethylated DNA is plotted against real the
proportions of both DNAs. The relative fluorescence
A B
genomic
DNA
PCR:
Primer extension:
Fig. 1 Schematic depiction of reaction steps used for the quantitative
(a) and qualitative (b) analysis of MGMT promoter methylation. Grey
boxes indicate genomic DNA or PCR products, small black boxes
indicate methylated CpG islands and open boxes indicate unmethy-
lated CpG islands (not drawn to scale). Arrows indicate primers used
for PCR and primer extension
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intensity of the primer extension products clearly reflects the
proportion of methylated DNA (Fig. 2; r = 0.977).
Tissue samples in pathology departments are routinely
stored as formalin-fixed and paraffin-embedded (FFPE)
tissue blocks. This preparation is unsuitable for many
downstream molecular biology techniques, because of
extensive fragmentation and modification of nucleic acids.
As a consequence, the commonly used gel-based MGMT
methylation assay, which gives rise to a PCR product of
290 bp, failed to yield amplification products in 25–33% of
cases [14, 21]. In contrast, both the qualitative and the
quantitative method used in this study, which give rise to
significantly shorter amplicons (\170 bp) than the gel-
based method, provided amplification products for all 290
glial tumours that were analysed. Sixteen percent of the
paraffin blocks were older than four years and some were
up to 20 years old; all of these provided informative
results.
To investigate whether the quantitative assay is repro-
ducible using FFPE material, a series of ten glioma cases,
nine of which were positive by the qualitative assay, were
analysed using the quantitative assay. Figure 3a illustrates
the reproducibility among independent replicates, in par-
ticular at higher values (SD maximum ±20%). In conclu-
sion, the quantitative assay is suitable for analysis of FFPE
material.
Finally, the sensitivity of the assay was determined by
DNA titration experiments. As shown in Fig. 3b, MGMT
promoter methylation could be determined from as little as
0.4 ng genomic DNA.
Comparison of qualitative and quantitative methods
As indicated in Fig. 3a, analysis of a small number of
tumours revealed that the quantitative and qualitative
assays are in very good agreement (Fig. 3a). To address
this issue on a larger scale, 290 glial tumours were com-
pared for MGMT promoter methylation using the qualita-
tive and quantitative assays. Samples with detectable
methylation were scored as positive. As shown in Table 1,
concordant test results were obtained for *90% of samples
(P \ 0.0001). Among the 30 samples that provided dis-
cordant results, 29 were MGMT methylation-positive by
Fig. 2 Linear correlation between the percentage of methylated DNA
and relative fluorescence signal. Genomic DNA from U87 (100%
methylated) and PBMC cells (unmethylated) were mixed at different
concentrations and analysed using the quantitative assay. The relative
intensity of the fluorescence signal for methylated and unmethylated
DNA is plotted against the real proportions of methylated DNA
(n = 3)
Fig. 3 Reliability of the quantitative assay. a Reproducibility.
Glioma tissues were excised from FFPE material and the percentage
of methylated DNA for the MGMT promoter was determined using
the quantitative assay. Values were normalized to a control containing
equal amounts of methylated and unmethylated DNA and presented
as mean ± SD (n = 4) relative to methylated DNA. Replicates are
derived from independent DNA conversion experiments. The result of
the qualitative analysis is shown below. b Sensitivity. Bisulfite-treated
DNA containing equal amounts of methylated and unmethylated
DNA was titrated and analysed using the quantitative method. Values
are presented as mean ± SD (n = 3)
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the quantitative assay and only one was methylation-
negative. In most of these cases, the quantitative assay gave
rise to a relatively low fluorescence signal for the meth-
ylated form of DNA, suggesting that this method is more
sensitive than the qualitative assay. Consistent with these
findings, 25 out of 28 samples turned out to be MGMT-
positive when subjected to PCR using the primer pair
MU_forward and MU_rv followed by a nested PCR using
the methylation-specific primers (data not shown). How-
ever, for some samples, discordant results were reproduc-
ibly obtained although the fluorescent signal for the
methylated form was relatively high by the quantitative
assay.
To better understand the discrepancy of results obtained
by the two methods, two samples were selected for further
analysis. For both samples approximately 80% MGMT
promoter methylation was observed, as indicated by the
quantitative assay, but only sample #2 was positive by the
qualitative assay. Bisulfite-treated DNA was amplified
using the primer pair MU_forward and MU_rv and cloned
into pGEM-T easy vector. Ten individual clones were
selected from each sample and sequenced. The result of
this analysis is summarized in Fig. 4. Cytosine residues
that do not form part of CpG dinucleotides were all
converted to thymidine indicating that bisulfite conversion
was efficient. Interestingly, both samples revealed a rela-
tively high degree of methylation of CpG dinucleotides,
despite the fact that sample #1 was negative by the
qualitative assay. Both samples showed a heterogeneous
methylation pattern within the binding site of primer
M_forward (Fig. 4, upper grey box) suggesting that
binding of this primer to its target DNA requires the
formation of mismatches in order that the polymerase
reaction can proceed. However, the finding that the
quantitative, but not the qualitative, assay provided a
positive result for sample #1, indicates that the latter assay
is more restrictive for fully methylated DNA. Consistent
with this result, the degree of methylation within the
binding site of primer M_forward was higher for sample
#2 than for sample #1.
Gliomas are heterogeneous for MGMT promoter
methylation
It may be inferred from the results in Fig. 3a that individual
glioma cells within a given tumour sample are remarkably
inhomogeneous with regard to MGMT promoter methyla-
tion. One might object that ‘‘intrinsic contamination’’ of
tumour tissue samples by non-neoplastic intratumoral
accessory structures (e.g., blood vessels, hematogeneous
inflammatory cells, microglia, etc.) might contribute to
such heterogeneity. However, care was taken to select
tumour tissues containing at least 70% of neoplastic tis-
sues. To determine the relative amount of tumour DNA in
our samples, we took advantage of the fact that a relatively
high proportion of gliomas exhibit deletion of chromosome
arms 1p and/or 19q. LOH was assessed for microsatellite
markers on chromosomal regions 1p36 and 19q13. The
allelic status of tumour DNA was compared with the DNA
from the patient’s peripheral blood. If a tumour with a
LOH 1p/19q consists of pure tumour cells we would expect
a complete loss of one allelic site of an informative
microsatellite marker. In contrast, contamination with
stroma cells leads to an incomplete loss of this region
(Electronic Supplementary Material, Fig. 1). The relative
loss of signal intensity of a microsatellite in the tumour
tissue plotted against the signal intensity of that same
microsatellite marker in the normal tissue can be used as a
measure of the proportion of tumour cells in the prepara-
tion [22]. In our series, 21 oligodendrogliomas, 24 oligo-
astrocytomas, 9 astrocytomas and 52 glioblastomas
contained an LOH 1p and/or 19q. In Fig. 5, the percentage
of methylated DNA of tumour samples corrected for the
relative signal intensity of microsatellites on chromosomes
Table 1 Correlation of quantitative and qualitative assays for
MGMT promoter methylation
Qualitative PCR Quantitative PCRa n Pb
- ?
MGMT? 1 128 290 \0.0001
MGMT- 132 29
a Samples with % MGMT [ 0 were scored as positive
b P-values were calculated by the v2 method (two by two table
Pearson’s analysis, two-tailed)
#2
#1
#2
#1
100% 0%
#2
#1
75% 50% 25%
Fig. 4 Frequency of methylation of individual CpG islands. PCR
products of the quantitative assay were subcloned and ten indepen-
dent clones were sequenced. The percentage of methylated DNA, as
indicated by the number of clones containing a cytosine residue at a
specific position, was determined. Both samples gave rise to 80%
methylation using the quantitative assay, but only sample #2 provided
a positive result by the qualitative assay. Primer sites used for primer
extension (quantitative method; upper grey box) and primer sites for
PCR (qualitative method; upper and lower grey box) are indicated
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1p or 19q was plotted against uncorrected values. Data
points for tissue samples containing 100% tumour cells
align along the diagonal dot line in the dot blot (Fig. 5).
Figure 5 illustrates that most data points fall on or near the
diagonal line indicating that most samples were not sig-
nificantly contaminated with non-neoplastic cells. From
these results we may conclude unequivocally that gliomas
have relatively high heterogeneity in the pattern of pro-
moter methylation of individual neoplastic cells.
Comparison of glioma subtypes for MGMT
promoter methylation
In agreement with published results [11], the quantitative
MGMT promoter methylation assay provided at least some
degree of promoter methylation in 81% (25/31) of oligo-
dendrogliomas (WHO grade II–III), 68% (27/40) of oli-
goastrocytomas (WHO grade II–III), 42% (23/55) of
astrocytomas (WHO grade II–III), and 50% (82/164) of
glioblastomas (WHO grade IV). However, it is unknown if
glioma entities also differ in their relative degree of
intratumoural methylation heterogeneity. As shown in
Fig. 6, methylation-positive oligodendrogliomas and oli-
goastrocytomas turned out to be the most homogeneous
groups with an average percentage of cells with promoter
hypermethylation of 75%. An increased tendency for int-
ratumoural methylation heterogeneity was noted for
methylation-positive astrocytomas (59%), but this did not
reach statistical significance. In contrast, methylation-
positive glioblastomas were highly heterogeneous for
MGMT promoter methylation, which was statistically
significant, with an average percentage of cells with
hypermethylated MGMT promoter of 55% (Fig. 6).
Correlation between MGMT promoter methylation
and LOH 1p
As shown in Fig. 7a, there was also a significant difference
in the percentage of cells with promoter hypermethylation
of oligodendrogliomas and oligoastrocytomas with LOH
1p (69%), compared with tumours without LOH (30%)
(P \ 0.0001). In contrast, no significant correlation was
noted between the incidence of promoter methylation, as
indicated by the qualitative assay, and the incidence of
LOH 1p.
Within the astrocytoma group (including glioblastomas)
no correlation was observed between the degree of pro-
moter methylation and incidence of LOH 1p (Fig. 7b)
irrespective of the method used for MGMT analysis.
Notably, the degree of promoter methylation for both
subgroups (24–32%), as indicated by the quantitative
Fig. 5 Percentage of methylated DNA in the tumour samples
corrected for the relative amount of tumour DNA. The relative
amount of tumour DNA in the tissue samples was calculated from the
loss of signal intensity of informative microsatellites on chromosome
arms 1p or 19q in the tumour sample relative to a reference DNA
from peripheral blood monocytes from the same patient. The
percentage of methylated DNA corrected for the relative amount of
tumour DNA was plotted against uncorrected values. Data points for
tissue samples containing 100% tumour DNA align along the
diagonal dot line (x = y) in the dot blot. Only tumours which contain
an LOH 1p and/or 19q were included. For direct comparison, LOH
and MGMT status were assessed from the same DNA sample. The
solid line represents the linear regression. Spearman correlation 0.96,
n = 74
Fig. 6 Comparison of the degree of promoter methylation between
oligodendrogliomas (O), oligoastrocytomas (OA), astrocytomas (A),
and glioblastomas (G). Statistical differences were calculated using
unpaired two-tailed t-test
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method, was similar to that obtained for oligodendroglio-
mas and oligoastrocytomas without LOH 1p.
Discussion
Over the past few years, a series of different methods,
including methylation-specific PCR [12, 14, 20, 23],
combined bisulfite restriction analysis [24], qMSP [21, 25],
single-nucleotide primer extension [26], MS-MLPA [27],
and pyrosequencing [28], have been established for deter-
mining promoter methylation of the MGMT gene, but it
remains unclear which assay performs best in predicting
TMZ sensitivity in gliomas. Some of these methods may
not be suitable for clinical settings, for they are either too
complex, prone to false-positive or false-negative results
(in particular if nested PCR is used), or provide no valid
result in a high proportion of cases. Quantitative methods
intuitively prove more reliable than qualitative assays,
which may be because a heterogeneous methylation pattern
of the MGMT promoter is very frequent in high-grade
gliomas. In addition, low degrees of MGMT methylation
can also be detectable in normal tissues including brain
tissue of some elderly individuals [29–31], which may lead
to false-positive results when qualitative methods are
applied. Analysis of MGMT protein expression by immu-
nohistochemistry will probably not gain wide acceptance,
because it is clearly less reliable and performs poorly when
compared with actual MGMT promoter methylation status
[32].
Here, we contribute an additional, primer extension-
based method, which enables quantitative assessment of
the methylation status of the MGMT promoter. This
method maps six diagnostically relevant CpG dinucleotides
[12–14, 20] including CpG4, which yielded the best pre-
diction among the CpG dinucleotides within this island for
overall survival in patients initially treated with radio-
therapy and TMZ [18].
This method is sensitive and consistently reproducible
using routinely processed histopathology samples (i.e.,
FFPE). In addition, it provides valid test results in a very
high percentage of cases. Although there is generally good
agreement between this method and the qualitative assay
used in this study, we feel that the quantitative method may
particularly appeal because of its robustness. Because not
every CpG site is methylated in methylation-positive
tumours, PCR-based methods have in common that binding
of the primer specific for methylated DNA to its target
DNA requires the formation of mismatches, which may
result in a lower efficiency of the polymerase reaction.
However, this has a much greater effect on PCR amplifi-
cation, for which high numbers of cycles are used (for
example in the case of MSP or qMSP), compared with
primer extension, for which only a few cycles are used. In
addition, MSP or qMSP normally interrogates more CpG
sites, because these methods depend on two methylation-
specific primers for the amplification and thus require more
sites to be methylated compared with primer extension-
based PCR. However, higher selectivity for fully methyl-
ated DNA is at the expense of lower sensitivity.
The qMSP assay yields binary data without a quantita-
tive measure of the contribution from unmethylated DNA.
Consequently, tumours with high proportions of tumour
cells with hypermethylated MGMT promoter will score the
same in the qMSP assay as tumours bearing only a few
hypermethylated cells, thus underestimating the heteroge-
neity of methylation. Moreover, qMSP may result in
underestimation of methylation in a tumour with gain of
chromosome seven if ACTB (which is located on this
chromosome) is used for normalisation [33]. In contrast,
pyrosequencing and primer-extension based PCR may be a
better estimate of the degree of intratumoral heterogeneity
of MGMT methylation. However, neither of these methods
Fig. 7 Degree of promoter methylation of gliomas with LOH 1p
compared with gliomas without LOH 1p. a Oligodendrogliomas and
astrocytomas. b Astrocytomas and glioblastomas. Statistical differ-
ences were calculated using unpaired two-tailed t-test
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enables us to discriminate whether the heterogeneity of
the methylation pattern is because of the presence of two
populations of tumour cells, one with a high degree and
one with a low degree of promoter methylation, or if this
is because of patchiness within a particular DNA strand.
However, on the basis of our results we can exclude the
possibility that the observed heterogeneity is because of
contamination with non-neoplastic cells.
On the basis of pyrosequencing [18, 34] or bisulfite
sequencing [35, 36], several studies have claimed meth-
ylation heterogeneity of the MGMT promoter in glio-
blastomas, although this has been challenged by others
[37]. In contrast, oligodendrogliomas seem to be more
homogeneous [28], but no study exists in which both
tumour entities were directly compared. It may also be
questioned in some cases to what extent non-neoplastic
cells may contribute to this heterogeneity. By analysing
290 diffusely infiltrating gliomas of adults with primer-
extension based PCR, we were able to confirm that
glioblastomas are indeed highly heterogeneous with
regard to promoter methylation of the MGMT gene while
oligodendrogliomas and oligoastrocytomas are signifi-
cantly more homogeneous. It is conceivable that patients
may respond less well to chemotherapy if the tumour is
heterogeneous for MGMT methylation, because this is
likely to result in rapid selection of tumour cells with a
low methylation status in the microevolutionary context
of a given glioma. In line with this notion, we show by
our quantitative method that the degree of promoter
methylation correlates with overall survival in a small
cohort of 60 glioblastoma patients treated with TMZ
(Electronic Supplementary Material, Fig. 2a). Notably,
patients with[70% methylation of their tumour DNA had
the longest overall survival (28 months), compared with
10 months for patients with unmethylated promoter
(P = 0.021). In contrast, patients with a degree of
methylation \70% had an life expectancy (17 months)
intermediate between those with unmethylated promoter
and those with hypermethylated promoter. Very consistent
results were also obtained by Dunn et al. [34] in a cohort
of 109 glioblastoma patients which were analysed by
pyrosequencing. In addition, in a retrospective study of
low-grade gliomas, we showed that the volumetric
response to chemotherapy correlates with the level of
MGMT-promoter methylation [38]. Single step or nested
MSP gave rise to a mean overall survival of
10–12 months for patients with unmethylated MGMT
promoter and 24–28 months for patients with methylated
MGMT promoter (Electronic Supplementary Material,
Figs. 2b, c). In conclusion, all methods enable prediction
of survival, but the quantitative method enables further
prediction of the magnitude of response to TMZ. It
remains to be shown whether oligodendrogliomas are
more sensitive to TMZ than astrocytomas, solely by vir-
tue of their more homogeneous MGMT promoter meth-
ylation status.
LOH 1p and 19q is regarded as an additional marker for
response to chemotherapy and, like MGMT promoter
methylation, is frequently detected in oligodendrogliomas.
Thus, an important question is whether these two genotypic
features are causally linked in oligodendrogliomas. Inter-
estingly, MGMT promoter methylation was prognostic and
not predictive for the outcome to adjuvant chemotherapy in
anaplastic oligodendroglial tumours [39, 40] and correlated
with other prognostic factors, for example 1p19q co-dele-
tions and isocitrate dehydrogene gene mutations [2, 28]), in
particular if quantitative methods for MGMT methylation
were used. Consistent with these results, a significant
correlation was noted in our study when the MGMT pro-
moter methylation status was assessed quantitatively.
However, no such correlation was seen in the astrocytoma
group, which has not been addressed so far. These results
may suggest that in oligodendrogliomas these markers may
reflect the less aggressive nature of these tumours, but the
underlying molecular mechanisms are unknown. In the
astrocytoma group, however, 1p19q deletions and promoter
methylation seem to be unlinked. It is possible that these
tumours may carry a general defect in regulating DNA
methylation leading to epigenetic silencing of multiple
genes including those linked to chemoresistance.
Our results indicate that quantitative analysis of the
methylation status of the MGMT promoter may be resorted
to for predicting the likelihood of response of glioma
patients to chemotherapy. Quantitative assessment of the
MGMT promoter methylation status, stratification of clin-
ical response to chemotherapy, and prognosis must be
correlated in a larger future study.
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